Director
Pfizer
Disclosure(s): Pfizer, Inc.: Salaried employee, Stocks/Bonds (Public Company)
Dr. Elliot DeHaan is a Director in Vaccines Clinical Research & Development at Pfizer, Inc. and an Infectious Disease physician by training. Dr. DeHaan serves as the lead clinician for the MONeT trial looking at the immunogenicity of Abrysvo(TM) in At-Risk and Immunocomrpomised persons. Prior to this trial he was a Medical Monitor and Efficacy Lead for the Phase III RENOIR trial (2021-2023).
Dr. DeHaan worked as an Infectious Disease physician in New York City (2010-2021) before arriving at Pfizer, focusing on the medical care of People Living with HIV and the prevention of HIV infection in at-risk populations. He lives in New York City.